


IMMUNOGEN

ImmunoGen, Inc.
Investor Relations Department
830 Winter Street
Waltham, MA 02451
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: IMGN

Last Trade:	6.03
Trade Time:	11:54 AM ET Nov 24, 2017
Change:	0.21  (+3.522%)
Day Range	5.85 - 6.12
52-Week Range	1.53 - 8.84
Volume	1,278,290

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roc... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Nov 7, 2017
[ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences](#)
- Nov 3, 2017
[ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results](#)
- Nov 1, 2017
[ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 59th ASH Annual Meeting](#)
- Oct 20, 2017
[ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2017 Financial Results](#)
- Oct 16, 2017
[ImmunoGen Announces Investigational New Drug Application for IMGN632 for Hematological Malignancies is Active](#)

Upcoming Events [\[View all \]](#)

- Nov 30, 2017 1:15 PM ET
[Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)
- Financials** [\[View all \]](#)
[Third Quarter Financial Results](#)
- Apr 28, 2017
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2017
[Quarterly Report \(10-Q\)](#)
- May 5, 2017
[Quarterly Report \(10-Q\)](#)